5 (633) In stock
Larotrectinib is approved by NICE as an option for NTRK fusion-positive solid tumours Picture: iStock Essential facts Larotrectinib is one of a new breed of cancer drugs designed to target specific changes in the DNA of cancer cells, rather than where the disease is growing in the body. This means patients, including children, with various cancer types may benefit from its use. It is particularly useful for those patients at an advanced stage of cancer, when other options are limited or have been exhausted.
A new Texas law makes better treatment options possible for cancer patients
How Immunotherapy Works To Treat Cancer
Call for action: Ensuring cancer treatment in times of COVID-19 •
Exploring Treatment Options
Experimental Cancer Therapy Shows Success in More Than 70 Percent of Patients in Global Clinical Trials
Scientists find possible genetic key to why some lymphoma patients don't respond to treatment
Why Do Cancer Treatments Stop Working? - NCI
New breast cancer treatment could help thousands of women - as it 'slashes risk of disease returning by a quarter
TGen News & Press Releases : TGen-UArizona medical school study points to possible new treatment options for breast cancer patients